AnalystBook Research · Company Intelligence

Viking Therapeutics, Inc.

VKTXNasdaq

Built from Viking Therapeutics, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Revenue was $0, while Net income decreased 227.1% to ($359.6M).

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue $0Watch
  • Profitability — Net income ($359.6M)Watch
  • Cash generation — Free cash flow N/ANote
  • Accounting — Formula-grey distress score · manipulation and earnings-quality screens not computedNote
  • Insiders — 1 buys; 8 sells in 365 daysOK
  • Capital — Comparable payout data unavailableNote

Business

Viking Therapeutics, Inc.: In March 2025, we entered into broad, multi-year manufacturing agreements, or the Manufacturing Agreements, with Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, covering both the active pharmaceutical ingredient, or API, and final finished product supply for VK2735.

Latest filings

  • 8-K · Company announcement2026-07-29
  • 10-Q · Quarterly report2026-07-29
  • 8-K · Company announcement2026-05-26
  • 10-Q · Quarterly report2026-04-30
  • 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Viking Therapeutics, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full VKTX record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.